Covid-19 roundup: Moderna posts $1.1B in Covid-19 vaccine deposits; Gilead CEO sees potential need for Veklury on a 'seasonal basis'
Moderna’s $MRNA executive team is clearly itching to get a near-term EUA for their Covid-19 vaccine.
The mRNA wunderkind posted an update on their pivotal trial for mRNA-1273, with a note that they have $1.1 billion in customer deposits for the vaccine.
Right now Moderna CEO Stéphane Bancel and his team are neck-and-neck with Pfizer/BioNTech in a race to unveil data on what could be the first vaccines for the pandemic. And he is not one to downplay the company’s prospects.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 94,000+ biopharma pros reading Endpoints daily — and it's free.